3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
11
Neoplasms
8
Fallopian Tube Neoplasms
8
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Neuroendocrine Tumors
3
Glioma
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Fanconi Anemia, Complementation Group D1
2
Cholangiocarcinoma
2
Uveal Melanoma
1
Urogenital Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
SCLC,Extensive Stage
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Interventions
Cyclophosphamide
5
fludarabine
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
peposertib
1
pembrolizumab
1
pasireotide
1
olaparib
1
lutetium Lu 177 dotatate
1
liposomal doxorubicin
1
fludarabine phosphate
1
anlotinib
1
aldesleukin
1
Zoledronic Acid
1
X-Rays
1
Tablets
1
Rosuvastatin Calcium
1
Quality of Life
1
Phantoms, Imaging
1
Midazolam
1
Leukapheresis
1
Interleukin-2
1
Injections
1
Immunotherapy, Adoptive
1
Immune Checkpoint Inhibitors
1
Ifosfamide
1
Digoxin
1
Dacarbazine
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma, Synovial
×
olaparib
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled